BioSpace News Archive

Researchers found that augmenting estrogen levels in postmenopausal women who had tested positive for SARS-CoV-2 might help reduce one’s risk of death from COVID-19.

By the end of the CREDIT-1 study, patients experienced a significant reduction in low-density lipoprotein cholesterol compared to the placebo group.

Research Roundup for February 18

It’s not clear if the recent deaths reported in FAERS resulted from the patients taking Aduhelm. This article takes a deep dive into this controversy.

In addition to massive layoffs – around 60% of its workforce – Yumanity also said it is considering “strategic alternatives” to its financial woes, including the possibility of selling or merging.

Edison Oncology Holding Corp. (“Edison Oncology”), today announced, that the first patient has received treatment with Orotecan (irinotecan HCI oral solution) in a Phase I/IIa clinical trial for patients with recurrent pediatric solid tumors.

Discovery Life Sciences™ (Discovery), the biospecimen and biomarker specialists™, today announced the expansion of its GMP-compliant, clinical- grade product portfolio with the launch of Discovery Cryo Leukopaks™ (GMP).

Confluent Medical Technologies (“Confluent”), a leading materials science, development, and manufacturing partner to medical device manufacturers, today announced the closing of a majority investment from TPG Capital, the private equity platform of alternative asset management firm TPG.

Immune-Onc Therapeutics, Inc. (“Immune-Onc”), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for IO-202, a first-in-class myeloid checkpoint inhibitor targeting leukocyte immunoglobulin-like receptor B4 (LILRB4, also known as ILT3) for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML).

Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, today announced it has entered a collaboration with the Pathology Department at Massachusetts General Hospital to develop an in vitro diagnostic (IVD) that evaluates sensitivity of solid tumors to poly-ADP ribose polymerase (PARP) inhibitors, with an initial focus on ovarian, breast and prostate cancers.